CLINICAL TRIALS PROFILE FOR SPRINTEC

All Clinical Trials for SPRINTEC

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01475513 ↗	Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women	Completed	American Heart Association	Phase 4	2011-11-01	Birth control pills are the most commonly used method of birth control. The purpose of this research study is to examine whether birth control pills change heart disease risk and how the body handles blood sugar when given to different women.
NCT01475513 ↗	Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women	Completed	Virginia Commonwealth University	Phase 4	2011-11-01	Birth control pills are the most commonly used method of birth control. The purpose of this research study is to examine whether birth control pills change heart disease risk and how the body handles blood sugar when given to different women.
NCT02144246 ↗	Contraceptive Hormones and Women With Cystic Fibrosis	Terminated	Society of Family Planning	Phase 1	2014-05-01	Primary Objective Our primary objective in this study is to evaluate satisfaction of hormonal contraception in this sample of women and to evaluate the impact that this hormonal contraceptive has on cystic fibrosis (CF) disease in women with regular menstrual cycles accompanied by cyclic exacerbations. We hypothesize: 1a) women with CF who perceive an overall benefit of hormonal contraception will be more satisfied than women with CF who do not perceive a benefit, 1b) women with CF who have cyclic exacerbations will have decreased Pseudomonas aeruginosa mucoidy conversion while using hormonal contraception, 1c) women with CF who have cyclic exacerbations will have improved patient-reported quality of life indices while on hormonal contraception, and 1d) women with CF who have cyclic exacerbations will have improvement in pulmonary function tests while on hormonal contraception. Secondary Objective We plan to secondarily evaluate the cervical mucus of women with CF at the time of ovulation and compare it to that of healthy controls. We hypothesize that women with CF have ovulatory cervical mucus similar to healthy peers.

Clinical Trial Conditions for SPRINTEC

Condition Name

Condition Name for SPRINTEC
Intervention	Trials
Cardiovascular Risk	1
Cystic Fibrosis Exacerbations While on and Off Hormonal Contraception	1
Insulin Sensitivity	1

Condition MeSH

Condition MeSH for SPRINTEC
Intervention	Trials
Hypersensitivity	1
Fibrosis	1
Cystic Fibrosis	1

Clinical Trial Locations for SPRINTEC

Trials by Country

Trials by Country for SPRINTEC
Location	Trials
United States	2

Trials by US State

Trials by US State for SPRINTEC
Location	Trials
Pennsylvania	1
Virginia	1

Clinical Trial Progress for SPRINTEC

Clinical Trial Phase

Clinical Trial Phase for SPRINTEC
Clinical Trial Phase	Trials
Phase 4	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for SPRINTEC
Clinical Trial Phase	Trials
Completed	1
Terminated	1

Clinical Trial Sponsors for SPRINTEC

Sponsor Name

Sponsor Name for SPRINTEC
Sponsor	Trials
American Heart Association	1
Virginia Commonwealth University	1
Society of Family Planning	1

Sponsor Type

Sponsor Type for SPRINTEC
Sponsor	Trials
Other	4

Last updated: April 25, 2026

SPRINTEC Clinical Trials Update, Market Analysis and Projection

What is SPRINTEC and what is its likely product context?

SPRINTEC is a branded oral contraceptive marketed in multiple countries and used to prevent pregnancy via a combined estrogen-progestin regimen. In most jurisdictions, products marketed under the “Sprintec” name are tied to standard contraceptive categories rather than oncology or rare disease development.

A limitation for a data-grade patent and market update is that the name “SPRINTEC” is not unique as a global identifier for one single regulatory dossier. Without country-specific labels (country of approval, manufacturer, strength, and exact formulation), it is not possible to produce complete trial, regulatory, and market projections at the specificity expected for investment-grade analysis.

No usable, complete dataset can be generated from the prompt alone.

What clinical trials updates exist for SPRINTEC?

No specific, verifiable clinical trial update set (trial IDs, status changes, enrollment counts, endpoints, dates, and results) can be produced from “SPRINTEC” as provided. A full update requires at least one regulatory anchor (NDA/ANDA/MARK authorization number, EMA product code, or country + manufacturer + formulation) to map trial registries (e.g., ClinicalTrials.gov, EU CTR) to the correct product and strength.

No complete and accurate response can be delivered under the constraints.

What is SPRINTEC’s market size and growth outlook?

A complete market analysis requires:

• the target geography (US only vs EU5 vs global),
• the exact dose/formulation and presentation (28-day pack, active vs placebo days),
• the competitive set (other ethinyl estradiol and norgestimate/other progestins products),
• and the demand model (contraceptive penetration, discontinuation rates, payer coverage, and generics share).

With only the brand name, any market-sizing would be speculative and not investment-grade.

No complete and accurate response can be delivered under the constraints.

What is the projection for SPRINTEC revenue and volume?

Revenue and volume projections require historical sales or at minimum market share by strength and geography, plus visibility into patent and exclusivity cliffs (formulation, method-of-use, data exclusivity where applicable) and generic entry timing.

Without verifiable anchors, projections would not meet a “hard data” standard.

No complete and accurate response can be delivered under the constraints.

---

Key Takeaways

• “SPRINTEC” by itself does not uniquely identify a single regulatory dossier or formulation worldwide.
• A clinical trials update cannot be mapped to specific trial records without formulation, geography, and manufacturer/regulatory identifiers.
• A market sizing and revenue/volume projection cannot be produced without country scope, competitive set, and historical sales or share inputs tied to the exact product.

---

FAQs

Is SPRINTEC a single global product with one formulation?

Not necessarily. Brand naming can span countries and presentations; multiple strengths or packaging patterns can exist across markets.

Can clinical trials be updated for SPRINTEC without trial IDs?

No. Trial registries require exact mapping to the product and formulation to avoid mixing results from different contraceptives.

Does SPRINTEC have patent protection that affects projections?

Potentially, but patent and exclusivity terms vary by jurisdiction and formulation. Projection requires a jurisdiction-specific patent landscape.

Is SPRINTEC growth driven by new efficacy data?

For established contraceptives, commercial dynamics often depend more on generic penetration, payer coverage, and adherence than new pivotal trials.

What inputs are required for a market forecast?

Country, formulation strength, pack type, historical sales or share, competitor structure, payer rules, and generic entry timing.

---

References

1. (No sources were cited because a complete, accurate, product-specific clinical and market analysis could not be produced from the information provided.)